Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase II: To evaluate the rate of patients alive and progression free at 6 months, assessed by the investigator according to RECIST criteria, version 1.1. Phase III: To assess and compare the Progression Free Survival (PFS) of lanreotide versus placebo according to RECIST criteria (version 1.1, Appendix 3), assessed by the investigator.
Critère d'inclusion
- Non-resectable duodeno-pancreatic neuroendocrine tumours after first line treatment